Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Gilead Launches PIII Remdesivir Trials for COVID-19 in Japan
Gilead Sciences said on April 14 that two global PIII trials for its investigational antiviral remdesivir have been initiated also in Japan for the treatment of patients with moderate to severe novel coronavirus disease COVID-19, with the first patient dosed…
To read the full story
Related Article
- PMDA Updates Veklury Label to Allow Its Use in Moderate COVID-19
January 8, 2021
- Check Latest Info and Make Careful Decision on Veklury Use: PMDA Review Report
May 19, 2020
- Chuikyo OKs Special Mixed Care Scheme for Veklury
May 11, 2020
- Japan Approves Remdesivir as First Drug for COVID-19
May 8, 2020
- Gilead Japan Expected to Offer Remdesivir for Free for Now
May 7, 2020
- Gilead Files Remdesivir for COVID-19 in Japan
May 4, 2020
- Japan Likely to Take FDA’s Anticipated EUA as Cue for “Special” Remdesivir OK
May 1, 2020
- Japan to Quickly Utilize “Special Approval” Scheme for Remdesivir after It’s OK’ed Overseas: Minister
April 30, 2020
- Japan Might Approve Gilead’s Remdesivir for COVID-19 in May
April 28, 2020
- Gilead Japan to Seek Early Remdesivir Filing If Initial Data Prove Positive: Development Chief
April 16, 2020
- Gilead-Sponsored Remdesivir Trial Expected to Start This Month: Minister
April 3, 2020
- Japan to Join NIH-Sponsored COVID-19 Trial for Gilead’s Remdesivir
March 24, 2020
- Gilead Launches PIII Studies for Remdesivir for COVID-19, Japan Included
February 28, 2020
BUSINESS
- Expert Calls for Greater Awareness of LC-FAOD after Dojolvi Debut
June 30, 2026
- Toho Defense Measure Scraped through Shareholder Vote: Report
June 30, 2026
- Enhertu Snags EU Approval in HER2 Positive Solid Tumors
June 30, 2026
- Datroway Grabs Positive CHMP Opinion in 1st-Line TNBC
June 30, 2026
- Tanabe Gets Thai Approval for Diabetes Drug Canalia
June 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…